On the stock market since 2021, it operates in the world of health and science. It has 10,000 employees. Now — the numbers.
This is an established company with proven profits.
The gap is $8.2B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price looks reasonable next to what the company earns.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 65% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $0.08 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales grew only 0% a year on average. At this size, speeding back up is not easy.
The stock trades 18% above the average analyst price target.
On our five-subject report card, OGN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: OGN is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.